SEC Form SC 13G/A filed by Oncocyte Corporation (Amendment)

2/14/24 3:47:19 PM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $OCX alert in real time by email

SC 13G/A 1 OncoCyte13g123123t.txt OCX 13G/A THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OncoCyte Corporation (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 68235C107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person?s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 68235C107 (1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only): AWM Investment Company, Inc. (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a)___ b)___ (3) SEC Use Only (4) Citizenship or Place of Organization: Delaware, United States Number of Shares Beneficially Owned by Each Reporting Person With (5) Sole Voting Power: 754,286** (6) Shared Voting Power: 0** (7) Sole Dispositive Power: 754,286** (8) Shared Dispositive Power: 0** (9) Aggregate Amount Beneficially Owned by Each Reporting Person: 754,286** (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): (11) Percent of Class Represented by Amount in Row (9): 9.1%** (12) Type of Reporting Person (See Instructions): IA **AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Cayman Fund, L.P. (CAYMAN), Special Situations Fund III QP, L.P. (SSFQP), Special Situations Private Equity Fund, L.P. (SSPE) and Special Situations Life Sciences Fund, L.P. (SSLS). (CAYMAN, SSFQP, SSPE, and SSLS will hereafter be referred to as the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 146,237 shares of Common Stock of the Issuer (the Shares) and 656,661 Warrants*** to purchase 32,833 Shares of Common Stock held by CAYMAN, 608,049 Shares and 2,345,216 Warrants*** to purchase 117,261 Shares of Common Stock held by SSFQP, 375,234 Warrants*** to purchase 18,762 Shares of Common Stock held by SSPE, and 375,234 Warrants*** to purchase 19,762 Shares of Common Stock held by SSLS. See Items 2 and 4 of this Schedule for additional information. *** The Warrants described herein may only be exercised to the extent that the total number of Common Shares then beneficially owned does not exceed 4.99% of the outstanding shares. Item 1(a). Name Of Issuer: OncoCyte Corporation Item 1(b). Address of Issuer?s Principal Executive Offices: 15 Cushing Irvine, California 92618 Item 2(a). Name of Person Filing: The person filing this report is AWM Investment Company, Inc., a Delaware corporation (AWM), which is the investment adviser to Special Situations Cayman Fund, L.P., a Cayman Islands Limited Partnership (CAYMAN), Special Situations Fund III QP, L.P., a Delaware limited partnership (SSFQP), Special Situations Private Equity Fund, L.P., a Delaware limited partnership (SSPE) and Special Situations Life Sciences Fund, L.P., a Delaware limited partnership (SSLS), (CAYMAN, SSFQP, SSPE and SSLS, will hereafter be referred to as the Funds). The principal business of each Fund is to invest in equity and equity-related securities and other securities of any kind or nature. David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are members of: SSCayman, L.L.C., a Delaware limited liability company (SSCAY), the general partner of CAYMAN; MGP Advisers Limited Partnership, a Delaware limited partnership (MGP), the general partner of SSFQP; MG Advisers, L.L.C., a Delaware limited liability company (MG), the general partner of SSPE and LS Advisers, L.L.C., a New York limited liability company (LS). Greenhouse and Stettner are also controlling principals of AWM. Item 2(b). Address of Principal Business Office or, if None, Residence: The principal business address for AWM is c/o Special Situations Funds, 527 Madison Avenue, Suite 2600, New York, NY 10022. Item 2(c). Citizenship: AWM is a Delaware Corporation. Item 2(d). Title of Class of Securities: Common Stock, No Par Value Item 2(e). CUSIP No.: 68235C107 Item 3. If This Statement Is Filed Pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a: Not Applicable. Item 4. Ownership (a) Amount Beneficially Owned: 754,286** (b) Percent of Class: 9.1%** (c) Number of Shares as to which the person has: (i) sole power to vote or to direct the vote: 754,286** (ii) shared power to vote or to direct the vote: 0** (iii) sole power to dispose or to direct the disposition of: 754,286** (iv) shared power to dispose or to direct the disposition of: 0** ______________________________________________________________________ ** AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole voting and investment power over 146,237 shares of Common Stock of the Issuer (the Shares) and 656,661 Warrants*** to purchase 32,833 Shares of Common Stock held by CAYMAN, 608,049 Shares and 2,345,216 Warrants*** to purchase 117,261 Shares of Common Stock held by SSFQP, 375,234 Warrants*** to purchase 18,762 Shares held by SSPE, and 375,234 Warrants*** to purchase 18,762 Shares of Common Stock held by SSLS. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN; MGP, the general partner of SSFQP; MG, the general partner of SSPE; and LS, the general partner of SSLS. Greenhouse and Stettner are also controlling principals of AWM. Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ___ Item 6. Ownership of More Than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person Not Applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 13, 2024 AWM INVESTMENT COMPANY, INC. By:/s/ Adam Stettner Name: Adam Stettner Title: Executive Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) -1-

Get the next $OCX alert in real time by email

Recent Analyst Ratings for

$OCX

Date	Price Target	Rating	Analyst
5/24/2022		Overweight → Equal-Weight	Stephens
3/14/2022		Overweight → Sector Weight	KeyBanc Capital Markets
3/11/2022	$11.00 → $6.00	Buy	Lake Street
3/11/2022	$5.00 → $4.00	Buy	Needham
1/7/2022	$3.10	Overweight	Stephens & Co.
1/6/2022	$3.10	Overweight	Piper Sandler
12/16/2021	$7.00 → $5.00	Buy	Needham
11/10/2021	$8.00 → $7.00	Buy	Needham

More analyst ratings

SEC Form SC 13G/A filed by Oncocyte Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for $OCX

$OCX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Financial Officer James Andrea S.

Chief Financial Officer James Andrea S. bought $100,000 worth of shares (33,670 units at $2.97) (SEC Form 4)

Large owner Broadwood Partners, L.P. bought $3,877,619 worth of shares (1,315,339 units at $2.95) (SEC Form 4)

$OCX Financials

Live finance-specific insights

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

$OCX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer James Andrea S. bought $100,000 worth of shares (33,670 units at $2.97) (SEC Form 4)

Large owner Broadwood Partners, L.P. bought $3,877,619 worth of shares (1,315,339 units at $2.95) (SEC Form 4)

Broadwood Partners, L.P. bought $7,057,688 worth of shares (2,420,000 units at $2.92) (SEC Form 4)

$OCX Large Ownership Changes

This live feed shows all institutional transactions in real time.

$OCX SEC Filings

$OCX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$OCX Market Insights

Live Market Insights

SEC Form SC 13G filed by Oncocyte Corporation

Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

SEC Form SC 13G filed by Oncocyte Corporation

SEC Form 10-Q filed by Oncocyte Corporation

Oncocyte Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 424B3 filed by Oncocyte Corporation

OncoCyte downgraded by Stephens

OncoCyte downgraded by KeyBanc Capital Markets

Lake Street reiterated coverage on OncoCyte with a new price target

Oncocyte Appoints Andrea James As CFO

Oncocyte's VitaGraft Kidney Diagnostic Test Shows Phase 2 Results In Transplant Monitoring, Published In New England Journal Of Medicine

Oncocyte VitaGraft Kidney Study Results Published In The New England Journal Of Medicine

$OCX Leadership Updates

Live Leadership Updates

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Oncocyte Appoints Andrea James as Chief Financial Officer

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

$OCX Press Releases

Fastest customizable press release news feed in the world

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Recent Analyst Ratings for
$OCX

$OCX
Insider Trading

$OCX
Financials

$OCX
Insider Purchases

$OCX
Large Ownership Changes

$OCX
SEC Filings

$OCX
Analyst Ratings

$OCX
Market Insights

$OCX
Leadership Updates

$OCX
Press Releases